$0.07
(Market cap
$2,910 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-8.9
-
Debt to Equity
0
-
Book Value
$7.6
-
EPS
$-3.5
-
Face value
--
-
Shares outstanding
165,219,501
10 Years Aggregate
CFO
$769.13 Mln
EBITDA
$1,448.50 Mln
Net Profit
$-1,808.54 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dyne Therapeutics Inc (DYN)
| -10.0 | -3.0 | 6.4 | 87.3 | 8.0 | -1.2 | -- |
|
BSE Sensex
| -8.7 | 3.6 | -7.5 | -4.2 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Dyne Therapeutics Inc (DYN)
| -17.0 | 76.3 | 14.8 | -2.5 | -43.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dyne Therapeutics Inc (DYN)
|
17.6 | 2,909.5 | 0.0 | -446.2 | -- | -55.7 | -- | 3.0 |
| 72.7 | 10,238.9 | 622.0 | -300.9 | -7.4 | -62.9 | -- | 16.7 | |
| 238.7 | 14,744.4 | 867.5 | 506.6 | -2.8 | -- | 26.8 | 78.1 | |
| 76.9 | 10,328.4 | 105.8 | -829.6 | -718.2 | -- | -- | 60.3 | |
| 48.2 | 12,105.3 | 2,375.5 | 833.4 | 40.8 | 40.7 | 15.9 | 5.2 | |
| 95.7 | 12,689.8 | 1,080.2 | -433.2 | -29.6 | -- | -- | 55.7 | |
| 8.5 | 8,913.0 | 141.0 | -854.5 | -97.9 | -- | -- | 0.0 | |
| 510.0 | 11,759.3 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.9 | |
| 424.0 | 12,109.3 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.7 | 19.9 | |
| 330.0 | 9,200.6 | 0.0 | -326.5 | -- | -37.2 | -- | 10.7 |
Shareholding Pattern
View DetailsAbout Dyne Therapeutics Inc (DYN)
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics,... including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Read more
-
Chief Operating Officer
Ms. Susanna Gatti High M.B.A.
-
Chief Operating Officer
Ms. Susanna Gatti High M.B.A.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Dyne Therapeutics Inc (DYN)
What is the current share price of Dyne Therapeutics Inc (DYN) Today?
The share price of Dyne Therapeutics Inc (DYN) is $17.61 (NASDAQ) as of 08-May-2026 16:00 EDT. Dyne Therapeutics Inc (DYN) has given a return of 8.02% in the last 3 years.
What is the current PB & PE ratio of Dyne Therapeutics Inc (DYN)?
Since, TTM earnings of Dyne Therapeutics Inc (DYN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-5.63
|
2.58
|
|
2024
|
-7.57
|
3.81
|
|
2023
|
-3.46
|
8.94
|
|
2022
|
-3.68
|
2.41
|
|
2021
|
-4.11
|
1.66
|
What is the 52 Week High and Low of Dyne Therapeutics Inc (DYN)?
The 52-week high and low of Dyne Therapeutics Inc (DYN) are Rs 25.00 and Rs 8.06 as of 10-May-2026.
What is the market cap of Dyne Therapeutics Inc (DYN)?
Dyne Therapeutics Inc (DYN) has a market capitalisation of $ 2,910 Mln as on 08-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Dyne Therapeutics Inc (DYN)?
Before investing in Dyne Therapeutics Inc (DYN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.